山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (6): 21-24.doi: 10.6040/j.issn.1673-3770.1.2017.048

• 甲状腺癌的规范化诊断与治疗·专题笔谈 • 上一篇    下一篇

甲状腺癌与外周静脉血炎性相关指标

普布次仁1,刘吉峰2,巴罗3   

  1. 1.西藏自治区人民医院普外科, 西藏 拉萨 850000;
    2.四川省肿瘤医院头颈外科, 四川 成都 610047;
    3.西藏自治区人民医院耳鼻咽喉科, 西藏 拉萨 850000
  • 收稿日期:2017-11-06 出版日期:2017-12-16 发布日期:2017-12-16
  • 通讯作者: 巴罗. E-mail:bhanor@163.com
  • 基金资助:
    西藏自治区科技厅自然基金(Z2012A60G32/00);四川省医学会资助课题(S15077)

Relationship between thyroid cancer and hematological components of the systemic inflammatory response.

PUBU Ciren1, LIU Jifeng2, BA Luo3   

  1. 1. Department of General Surgery, Peoples Hospital of Tibet Autonomous Region, Lhasa 850000, Tibet, China;2. Department of Head and Neck Surgery, Sichuan Cancer Hospital, Chengdu 610047, Sichuan, China;3. Department of Otolaryngology, Peoples Hospital of Tibet Autonomous Region, Lhasa 850000, Tibet, China
  • Received:2017-11-06 Online:2017-12-16 Published:2017-12-16

PDF (PC)

889

摘要： 包括甲状腺癌在内的多种恶性肿瘤,证据表明其预后与反应系统的炎症反应的血液学指标相关。越来越多地研究关注甲状腺癌和中性-淋巴细胞比、血小板-淋巴细胞计数比值、C反应蛋白的关系。就这些血液学相关指标与甲状腺癌的研究进展做一综述。

关键词: 甲状腺癌, 血小板-淋巴细胞比, 中性-淋巴细胞比

Abstract: In a variety of cancers, including thyroid cancer, hematological components of the systemic in ammatory response have been shown to have prognostic value.Most previous studies have focused on the relationship between thyroid cancer and hematological components, such as neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein.This paper aimed to report the advance of the association between these hematological data and thyroid cancer.

Key words: Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte count ratio, Thyroid cancer

中图分类号: 

  • R736.1
[1] Zhou GJ, Xiao M, Zhao LN, et al. MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis[J]. Genet Mol Res, 2015, 14(3):7279-7289.
[2] 王宇,马奔. 超声引导下热消融技术尚不适用于甲状腺癌及甲状腺滤泡性肿瘤治疗[J]. 山东大学耳鼻喉眼学报,2016, 30(2):20-22. WANG Yu, MA Ben. Ultrasound guided thermoablation does not fit for thyroid carcinoma and follicular neoplasm[J]. J Otolaryngol Ophthal Shandong Univ,2016, 30(2):20-22.
[3] Jiang K, Lei J, Chen W, et al. Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma[J]. Medicine(Baltimore), 2016, 95(40):5079.
[4] Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007, 18(1-2):171-182.
[5] Dalpiaz O, Pichler M, Mannweiler S, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma[J]. Br J Cancer, 2014, 110(10):2531-2536.
[6] Liu CL, Lee JJ, Liu TP, et al. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer[J]. J Surg Oncol, 2013, 107(5):493-497.
[7] Wenger FA, Jacobi CA, Zieren J, et al. Tumor size and lymph-node status in pancreatic carcinoma- is there a correlation to the preoperative immune function?[J]. Lang Arch Surg, 1999, 384(5):473-478.
[8] Guarino V, Castellone MD, Avilla E, et al. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1):94-102.
[9] Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773.
[10] Bradly DP, Reddy V, Prinz RA, et al. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases[J]. Surgery, 2009, 146(6):1099-1104.
[11] Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer[J]. Br J Cancer, 2012, 107(4):695-699.
[12] Clarke SJ, Chua W, Moore M, et al. Use of inflammatory markers to guide cancer treatment[J]. Clin Pharmacol Ther, 2011, 90(3):475-478.
[13] Seretis C, Gourgiotis S, Gemenetzis G, et al. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study[J]. Am J Surg, 2013, 205(6):691-696.
[14] Kim JY, Park T, Jeong SH, et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas[J]. Endocrine, 2014, 46(3): 526-531.
[15] Kocer D, Karakukcu C, Karaman H, et al. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders?[J]. Asian Pac J Cancer Prev, 2015, 16(9):3875-3879.
[16] Liu J, Du J, Fan J, et al. The Neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma[J]. ORL J Otorhinolaryngol Relat Spec, 2015, 77(2):109-116.
[17] Kim SM, Kim EH, Kim BH, et al. Association of the preoperative neutrophil-to-ymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer[J]. Endoc Metab(Seoul), 2015, 30(4): 494-501.
[18] Liu JF, Ba L, Lv H, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis[J]. Sci Rep, 2016, 6:38551.
[19] Cho JS, Park MH, Ryu YJ, et al. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer[J]. Ann Surg Treat Res, 2015, 88(4):187-192.
[20] Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis[J]. Sci Rep, 2015, 5:12493.
[21] Lang BH, Ng CP, Au KB, et al. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?[J]. World J Surg, 2014, 38(10):2605-2612.
[22] Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer[J]. Future Oncol, 2010, 6(1):149-163.
[23] Yaylaci S, Tosun O, Sahin O, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer[J]. Asian Pac J Cancer Prev, 2016, 17(4):2321-2323.
[24] Sun C, Li Q, Hu Z, et al. Treatment and prognosis of anaplastic thyroid carcinoma: experience from a single institution in China[J]. PLoS One, 2013, 8(11):e80011.
[25] Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment[J]. J Clin Endocrinol Metab, 2011, 96(5):1237-1245.
[26] Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies[J]. Asian Pac J Cancer Pre, 2013, 14(1):243-248.
[27] Hou X, Jiang L, Chen C, et al. Different expression of erythrocyte sedimentation rate and c-reactive protein in papillary thyroid carcinoma and nodular goiter[J]. Clin Lab, 2015, 61(7):793-799.
[28] Stanciu AE, Serdarevic N, Hurduc AE, et al. IL-4,IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimotos thyroiditis[J]. Scand J Clin Lab Invest, 2015, 75(7):539-548.
[1] 张中华,王辉,王俊鑫,张美玲,张建,张恩东,潘新良. 腋窝入路腔镜手术和传统颈部开放手术治疗T1甲状腺癌的安全性和有效性对比研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 161-167.
[2] 杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161.
[3] 王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.
[4] 王安洋,李超友,薛刚,吴靖芳. 肠道菌群与甲状腺疾病的关系[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 132-139.
[5] 张轶轶,薛刚,金春亭. 外泌体在甲状腺癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 131-135.
[6] 潘新良. 加强甲状腺结节及恶性肿瘤的规范治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 1-12.
[7] 陈海兵, 卫亚楠, 许晓泉, 陈曦. 基于XGBoost人工智能结合CT构建甲状腺癌颈部淋巴结转移预测模型[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 40-45.
[8] 邓迪,刘均,李林珂,王吉,刘吉峰,吕丹,王海洋,甘卫刚,王君,李波,陈飞. 皮瓣二期重建策略应用于气管非环周缺损修复重建[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 52-57.
[9] 房忠菊, 张永侠, 赵建东, 纵亮, 翟性友, 李新建, 彭新, 任楠, 陈立伟, 刘明波. 甲状腺癌颈清扫术后乳糜漏的综合治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 64-68.
[10] 吕静荣,陈淳,马衍,谢晋. 儿童分化型甲状腺癌的临床特征及危险因素分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 88-94.
[11] 冯云,钟志明,陈国庆. 纳米碳在甲状腺乳头状癌隐匿性侧颈转移淋巴结清扫术中的临床应用价值[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 101-106.
[12] 马驰,郑桂彬,孙海清,吴国长,郭雅文,孔杨,宋西成,郑海涛. 加速康复外科理念应用于甲状腺癌手术100例[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 107-110.
[13] 王佳说,郭星,阎艾慧. 甲状腺乳头状癌颈淋巴结转移形成巨大囊性变的诊断总结[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 111-113.
[14] 高晓倩,姜震,耿琛琛,刘大昱,李荔. 术前超声评估分化型甲状腺癌颈部淋巴结转移[J]. 山东大学耳鼻喉眼学报, 2019, 33(1): 135-139.
[15] 邱杰,孙莎莎,孙彦. 美国癌症联合委员会第8版甲状腺癌TNM分期解读[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 5-8.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发